Brokerages Set SAB Biotherapeutics, Inc. (NASDAQ:SABS) PT at $10.00

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $10.00.

Several research firms have recently commented on SABS. Chardan Capital restated a “buy” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d)” rating on shares of SAB Biotherapeutics in a report on Monday, December 29th. Guggenheim assumed coverage on shares of SAB Biotherapeutics in a research report on Friday, December 19th. They set a “buy” rating and a $15.00 target price for the company. UBS Group assumed coverage on shares of SAB Biotherapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $7.00 price target on the stock. Finally, Wall Street Zen upgraded SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd.

SAB Biotherapeutics Price Performance

SABS stock opened at $4.42 on Friday. The business has a 50 day moving average price of $3.90 and a 200 day moving average price of $2.99. The company has a quick ratio of 10.50, a current ratio of 10.49 and a debt-to-equity ratio of 0.02. The stock has a market cap of $210.44 million, a price-to-earnings ratio of -1.43 and a beta of 0.58. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.38. Equities research analysts anticipate that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

A number of large investors have recently made changes to their positions in SABS. HB Wealth Management LLC purchased a new stake in SAB Biotherapeutics during the 3rd quarter worth about $618,000. Dimensional Fund Advisors LP acquired a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth about $32,000. ADAR1 Capital Management LLC acquired a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth about $30,000. Virtu Financial LLC purchased a new stake in shares of SAB Biotherapeutics during the third quarter worth about $40,000. Finally, Commodore Capital LP purchased a new position in shares of SAB Biotherapeutics during the 3rd quarter worth $8,847,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.